Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
strategic options
Biotech
Adaptimmune questions own longevity, axes preclinical funding
Adaptimmune is cutting enrollment for clinical programs and evaluating strategic options in efforts to save cash.
Gabrielle Masson
Mar 20, 2025 2:04pm
Struggling Relmada pays $3M for Tourette's asset from Asarina
Feb 7, 2025 11:00am
After 3rd phase 3 strike, Relmada's depression drug is out
Dec 9, 2024 2:30pm
Portage Biotech hints at potential closure as it halts programs
Apr 12, 2024 10:22am
Cash-strapped Gamida steps up search for strategic alternatives
Jan 29, 2024 8:41am
SQZ lays off 80% of staff, Regenxbio cuts 15%
Nov 9, 2023 8:23am
